These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 10530710)

  • 1. Antibody-targeted therapy for myeloid leukemia.
    Appelbaum FR
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
    Matthews DC
    Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
    Shannon-Dorcy K
    Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
    Countouriotis A; Moore TB; Sakamoto KM
    Stem Cells; 2002; 20(3):215-29. PubMed ID: 12004080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
    Andreasen RB; Olsson L
    J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15.
    Ball ED; Selvaggi K; Hurd D; Herzig R; Clark L; Malley V; Persichetti J; deMagelhaus-Silverman M
    Clin Cancer Res; 1995 Sep; 1(9):965-72. PubMed ID: 9816068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical evaluation of anti-lacto-N-fucopentaose III (CD15) monoclonal antibodies for ex vivo bone marrow purging in acute myeloid leukemia.
    Guyotat D; Shi ZH; Campos L; Rabat M; Bonnier S; Poncelet P; Laurent JC; Fiere D
    Bone Marrow Transplant; 1990 Dec; 6(6):385-90. PubMed ID: 1982926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
    Kotzerke J; Bunjes D; Scheinberg DA
    Bone Marrow Transplant; 2005 Dec; 36(12):1021-6. PubMed ID: 16247432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.
    Matthews DC; Badger CC; Fisher DR; Hui TE; Nourigat C; Appelbaum FR; Martin PJ; Bernstein ID
    Cancer Res; 1992 Mar; 52(5):1228-34. PubMed ID: 1531324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
    Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
    Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
    Nguyen DH; Ball ED; Varki A
    Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mylotarg approved for patients with CD33+ acute myeloid leukemia.
    Sorokin P
    Clin J Oncol Nurs; 2000; 4(6):279-80. PubMed ID: 11899326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody therapy in acute myeloid leukemia.
    Feldman EJ
    Curr Hematol Rep; 2003 Jan; 2(1):73-7. PubMed ID: 12901157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current uses of monoclonal antibodies in the treatment of acute leukemia.
    Ruffner KL; Matthews DC
    Semin Oncol; 2000 Oct; 27(5):531-9. PubMed ID: 11049021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
    Amadori S; Stasi R
    Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.